Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients

Ping Chen,Haolin Song,Xu Wang,J. Guo,Jianfei Wang,Jianhua Zhou,Xiaohong Kang,Chaolei Jin,Yubo Cai,Zixuan Feng,Hainv Gao,Fang Lü,Lanjuan Li

DOI: https://doi.org/10.3389/fonc.2023.1170066

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1037742.].

What problem does this paper attempt to address?

Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

Jitao Wang,Tianlei Zheng,Yong Liao,Shi Geng,Jinlong Li,Zhanguo Zhang,Dong Shang,Chengyu Liu,Peng Yu,Yifei Huang,Chuan Liu,Yanna Liu,Shanghao Liu,Mingguang Wang,Dengxiang Liu,Hongrui Miao,Shuang Li,Biao Zhang,Anliang Huang,Yewei Zhang,Xiaolong Qi,Shubo Chen

DOI: https://doi.org/10.3389/fonc.2023.1278295

IF: 4.7

2023-08-31

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.986867.].

oncology
Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer

Peijie Chen,Yuting Gao,Si Ouyang,Li Wei,Min Zhou,Hua You,Yao Wang

DOI: https://doi.org/10.3389/fphar.2021.723153

IF: 5.6

2021-08-25

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2020.585255.].

pharmacology & pharmacy
Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Xiaofan Hu,Mingyang Bao,Jiacheng Huang,Lin Zhou,Shusen Zheng

DOI: https://doi.org/10.3389/fonc.2020.617539

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:CORRECTION article Front. Oncol., 20 November 2020Sec. Molecular and Cellular Oncology Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.617539
Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

TingAn Wang,HuaGe Zhong,YuZhou Qin,WeiYuan Wei,Zhao Li,MingWei Huang,XiaoLing Luo

DOI: https://doi.org/10.1155/2021/3179693

2021-02-09

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2020/3575038.].

biotechnology & applied microbiology,medicine, research & experimental
Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Lanlan Xiao,Xingqi Xu,Kaizhou Huang,Yalei Zhao,Lingjian Zhang,Lanjuan Li

DOI: https://doi.org/10.1155/2021/9875940

2021-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2019/3757149.].
Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer

Sheng Liu,Wenting Tang,Jing Cao,Mei Shang,Sun Hengchang,Jiao Gong,Bo Hu

DOI: https://doi.org/10.3389/fgene.2024.1357409

IF: 3.7

2024-01-26

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.904114.].

genetics & heredity
Corrigendum: Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China

Lan-Wei Guo,Zhang-Yan Lyu,Qing-Cheng Meng,Li-Yang Zheng,Qiong Chen,Yin Liu,Hui-Fang Xu,Rui-Hua Kang,Lu-Yao Zhang,Xiao-Qin Cao,Shu-Zheng Liu,Xi-Bin Sun,Jian-Gong Zhang,Shao-Kai Zhang

DOI: https://doi.org/10.3389/fonc.2022.871848

IF: 4.7

2022-03-03

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.766939.].

oncology
Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Haoran Qian,Na Yan,Xiaotong Hu,Junchang Jiang,Zhengzheng Cao,Dan Shen

DOI: https://doi.org/10.3389/fgene.2022.945357

IF: 3.7

2022-06-28

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.864499.].

genetics & heredity
Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

Yaxin Chen,Lei Xia,Yuxuan Peng,Gang Wang,Liyun Bi,Xue Xiao,Cui Li,Weimin Li

DOI: https://doi.org/10.3389/fonc.2023.1309950

IF: 4.7

2023-11-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.947808.].

oncology
Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Haiyang Zhao,Kexin Luo,Meihan Liu,Yuanze Cai,Siman Liu,Shijuan Li,Yongsheng Zhao,Hongpan Zhang

DOI: https://doi.org/10.3389/fgene.2024.1531321

IF: 3.7

2024-12-04

Frontiers in Genetics

Abstract:This article is a correction to: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

genetics & heredity
Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Wan-Xin Peng,Fei Liu,Jia-Hong Jiang,Hang Yuan,Ziqiang Zhang,Liu Yang,Yin-Yuan Mo

DOI: https://doi.org/10.1016/j.gendis.2024.101352

2024-06-15

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2022.02.014.].
Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Jun Li,Sile Han,Cuiyun Zhang,Yanlin Luo,Li Wang,Ping Wang,Yi Wang,Qingxin Xia,Xiaoyan Wang,Bing Wei,Jie Ma,Hongle Li,Yongjun Guo

DOI: https://doi.org/10.3389/fonc.2021.840551

IF: 4.7

2022-01-14

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.655709.].

oncology
Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

Xinyao Hu,Hua Zhu,Shi Feng,Chaoqun Wang,Yingze Ye,Xiaoxing Xiong

DOI: https://doi.org/10.3389/fgene.2022.1117731

IF: 3.7

2023-01-16

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.1006357.].

genetics & heredity
Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study

Chenjun Huang,Meng Fang,Xiao Xiao,Hong Wang,Zhiyuan Gao,Jun Ji,Lijuan Liu,Erli Gu,Ya Li,Mengmeng Wang,Chunfang Gao

DOI: https://doi.org/10.1111/liv.15082

IF: 8.754

2021-10-31

Liver International

Abstract:BACKGROUND: GALAD is an algorithm model estimating the presence of hepatocellular carcinoma (HCC). However, the participants enrolled in the GALAD differ from those of Chinese subjects whose HCCs are mainly hepatitis B virus infection related. Therefore, the cross-sectional as well as longitudinal multicenter study was designed to assess the clinical performances of GALAD in the Chinese population.METHODS: A case-control study of 602 patients with HCC (34.10% within Barcelona Clinic Liver Cancer 0-A stage) and 923 subjects without HCC from five Chinese medical centres was conducted. Longitudinally the performances of GALAD identifying HCC were assessed using receiver operating characteristic curves analyses. Furthermore, the surveillance performance of GALAD for 204 HCC patients after radical surgery and for the early detection of HCC prospectively in an independent cohort of chronic hepatitis B were analysed, respectively.RESULTS: We found the GALAD identified early stage HCC at an area under the receiver operating characteristic curve (AUC) above 0.85 and outperformed significantly than AFP, PIVKAII, AFP-L3 and BALAD-2 respectively. Meanwhile the GALAD could stratify HCC into two distinct subgroups with high or low risks of overall survival and recurrence. The GALAD could detection HCC 24 (AUC: 0.848) or even 48 (AUC: 0.833) weeks before clinical diagnosis.CONCLUSIONS: Our study indicates that the GALAD exhibits outstanding performance in the early diagnosis, prognosis prediction as well as risk monitoring of HCC in our cross-sectional and longitudinal multicenter study of 1561 patients. GALAD should be implanted into clinical practice early so as to improve the clinical efficacy of individual biomarkers in HCC early monitoring and prognosis prediction.

gastroenterology & hepatology
Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Yongrong Lei,Xishu Wang,Heng Sun,Yuna Fu,Yichen Tian,Ludi Yang,Jianhua Wang,Feng Xia

DOI: https://doi.org/10.3389/fonc.2024.1438731

2024-07-10

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.601668.].
Corrigendum: Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis

Yong-Zheng Zhang,Amir Zeb,Lu-Feng Cheng

DOI: https://doi.org/10.3389/fimmu.2023.1168774

IF: 7.3

2023-02-28

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.1032819.].

immunology
Corrigendum to "Potential pre-COPD indicators in association with COPD development and COPD prediction models in Chinese: a prospective cohort study" [The Lancet Regional Health - Western Pacific 44 (2024) 100984].

Jing Fan,Liwen Fang,Shu Cong,Yang Zhang,Xiao Jiang,Ning Wang,Yahong Chen

DOI: https://doi.org/10.1016/j.lanwpc.2024.101033

2024-01-01

Abstract:[This corrects the article DOI: 10.1016/j.lanwpc.2023.100984.].
Corrigendum: Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer

Yang He,Yongxin Wu,Zhe Liu,Boping Li,Ning Jiang,Peng Xu,Abai Xu

DOI: https://doi.org/10.3389/fgene.2022.880633

IF: 3.7

2022-05-17

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2021.694777.].

genetics & heredity
Corrigendum: Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer

Anli Yang,Ying Zhou,Yanan Kong,Xiaoli Wei,Feng Ye,Lijuan Zhang,Xian Zhong,Mingyue Li,Shilin Lu,Xin An,Weikai Xiao

DOI: https://doi.org/10.3389/fimmu.2024.1372991

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.704557.].

immunology
Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients

Xinhua Chen,Huimin Zhang,Minghao Wang,Hao Liu,Yanfeng Hu,Tian Lin,Hao Chen,Mingli Zhao,Tao Chen,Guoxin Li,Jiang Yu,Liying Zhao

DOI: https://doi.org/10.3389/fimmu.2023.1235273

IF: 7.3

2023-06-15

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.783695.].

immunology

Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients

Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer

Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer

Corrigendum: Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China

Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study

Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Corrigendum: Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis

Corrigendum to "Potential pre-COPD indicators in association with COPD development and COPD prediction models in Chinese: a prospective cohort study" [The Lancet Regional Health - Western Pacific 44 (2024) 100984].

Corrigendum: Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer

Corrigendum: Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer

Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients